

Phase I study of oral artesunate in colorectal cancer

Submission date 03/12/2008	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 16/01/2009	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 27/11/2015	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Devinder Kumar

Contact details
Department of Colorectal Surgery
St George's NHS Healthcare Trust
Blackshaw Road
London
United Kingdom
SW17 0RS

Additional identifiers

Protocol serial number
07.0195, protocol v2.3 (9 September 2008)

Study information

Scientific Title
Phase I placebo controlled, randomised, double-blind tolerability and efficacy study of oral artesunate in patients with colorectal carcinoma

Study objectives

The primary objective of the study is to determine the anti-cancer effect of oral artesunate in colorectal adenocarcinoma defined as the proportion of malignant cells undergoing apoptosis.

Secondary outcome measures are to establish the tolerability of oral artesunate in colorectal cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Wandsworth Research Ethics Committee approved on 18th March 2008 (ref: 08/H0803/3)

Study design

Single-centre randomised double-blind placebo-controlled interventional study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Colorectal adenocarcinoma

Interventions

Subjects will be randomised to receive 200 mg artesunate or placebo orally once daily for 14 days whilst awaiting surgery for colorectal adenocarcinoma with curative intent.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Artesunate

Primary outcome(s)

A significant difference in the proportion of cells that exhibit apoptosis between the two treatment groups (placebo and artesunate), assessed at the time of surgery, after two weeks of drug treatment.

Key secondary outcome(s)

1. Tolerability of artesunate compared with placebo. Tolerability will be assessed according to conventional criteria used in clinical trials, and scored on standardised pro-formas.
2. Comparisons will also be made between baseline haematological and biochemical variables (full blood count, liver function tests, urea and electrolytes), and these measures repeated once treatment stops and before surgery

Assessed after one week and at the end of drug treatment.

Completion date

01/03/2010

Eligibility

Key inclusion criteria

1. Aged 21 - 80 years, male or female
2. With biopsy confirmed single primary site colorectal adenocarcinoma
3. With stages I - IIIb (defined according to conventional criteria)
4. With planned curative resection
5. With written, informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Contraindication to use of artesunate due to hypersensitivity
2. Pregnancy (of any stage)
3. History of hearing or balance problems
4. Immunosuppression or concomitant medication known to interact with artesunate
5. Weight less than 50 kg or greater than 100 kg
6. Severe anaemia (haemoglobin less than 8 g/dl)
7. Other planned intervention, apart from standard of care
8. Inability to give informed consent
9. Inability or unwillingness to take effective contraception in women of child-bearing age
10. Chronic kidney disease of NKF D/QOFI stage 3 or above (estimated glomerular filtration rate [eGFR] less than 60 ml/min)
11. Bilirubin greater than 2 x upper limit of normal in the absence of haemolysis, or known chronic liver disease

Date of first enrolment

01/03/2009

Date of final enrolment

01/03/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Department of Colorectal Surgery
London
United Kingdom
SW17 0RS

Sponsor information

Organisation
St George's, University of London (UK)

ROR
<https://ror.org/040f08y74>

Funder(s)

Funder type
University/education

Funder Name
St George's, University of London (UK)

Alternative Name(s)
St. George's

Funding Body Type
Private sector organisation

Funding Body Subtype
Universities (academic only)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/11/2014		Yes	No